The Big Reason IBM Is a Great Buy Before July 22 Earnings
IBM reports earnings on July 22 and the setup heading into that date combines a dividend streak most tech stocks cannot touch with an AI angle Wall Street has barely started to price in.
IBM (NYSE:IBM | IBM Price Prediction) ahead of its confirmed July 22 after-market report screens well for income-oriented portfolios: The model target puts base-case upside at 13.81%, prediction markets are already pricing in a beat and the dividend just got raised for the 31st year running. The setup carries high conviction on both valuation and catalyst timing.
Valuation With a Target Above Spot
On July 13, shares changed hands around $291.51 against a base-case target of $336.78 and a bull case of $355.64. Analyst coverage skews decisively positive at 15 Buy ratings against one Sell rating, and a beta of 0.68 means retirement accounts get the upside without the tech-sector whiplash.
Income That Compounds
The board pushed the quarterly dividend to $1.69, lifting the annualized forward payout to $6.76. That marks the 31st consecutive year of dividend increases, and management reaffirmed free cash flow growth of approximately $1 billion year-over-year in 2026. The check is written and the coverage is there.
The July 22 Catalyst Is Already De-Risked
Polymarket contracts show an 80.5% probability that Q2 Software revenue clears $7.9 billion, with 68.5% odds of topping $8.05 billion. IBM has beaten EPS estimates five consecutive quarters, and Q1 delivered 9.46% revenue growth with IBM Z mainframe revenue up 51%. Arvind Krishna quantified the overlooked piece on the call: a fully populated Z system now runs “about 450 billion inferences a day”, turning the mainframe from a cyclical hardware line into an AI inferencing engine the Street is still under-modeling.
The Head-to-Head Win
Against Accenture (NYSE:ACN), the pure-play consulting peer, IBM’s mix wins on every axis retirees care about. IBM Software grew 11.3% and Infrastructure 15.3% in Q1, while Infrastructure segment profit margin expanded to 15.8% from 8.6% year-on-year. Accenture carries no mainframe cycle, no equivalent recurring AI-inferencing hardware pull, and no 31-year dividend-raise streak. The head-to-head is a growth mix plus aristocrat-grade income against a single-lever consulting business.
Layer in the Confluent acquisition feeding live data into the GenAI pipeline, a P/E of 27 that leaves room and a more than 8% price appreciation in the past month and the setup writes itself.
The July 22 report is the near-term catalyst that will test the current setup.
Contact [email protected] for any questions or corrections.
Joel South covers large-cap stocks, dividend investing, and major market trends, with a focus on earnings analysis, valuation, and turning complex data into actionable insights for investors.
He brings more than 15 years of experience as an investor and financial journalist, including 12 years at The Motley Fool, where he served as an investment analyst, Bureau Chief, and later led the Fool.com investing news desk. He has also co-hosted an investing podcast and appeared across TV and radio discussing market trends.
